Home/Rege Nephro/Kenji Osafune
KO

Kenji Osafune

Founder, Director, Chief Scientific Advisor

Rege Nephro

Therapeutic Areas

Rege Nephro Pipeline

DrugIndicationPhase
TamibaroteneAutosomal Dominant Polycystic Kidney Disease (ADPKD)Preclinical
NPC Cell TherapyRenal DiseasesPreclinical
EPO-producing Cell TherapyRenal AnemiaPreclinical